Anas Younes, MD, is the Chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center and Professor ofMedicine at Weill-Cornell Medical College, New York, NY, USA. He has extensive experience in clinical and translational research in lymphoma. He was the Principal Investigator of the MD Anderson Cancer Center LymphomaSPORE grant, and is currently the Principal Investigator of the Memorial Sloan Kettering Cancer Center Lymphoma SPORE grant. He has lead more than 60 clinical trials in lymphoma. He has lead, in collaboration with colleagues from around the world, the pivotal trials that resulted in the US FDA approval of brentuximab vedotin and nivolumab for the treatment of patients with relapsed Hodgkin lymphoma. He has published more than 250 papers on lymphoma.

• Introduction.- Risk factors, etiology, and pathogenesis.- World Health Organization classification.- Staging.- Treatment overview.- Treatment of B-cell lymphomas.- Treatment of T-cell lymphomas.- Treatment of Hodgkin lymphoma.- Management of human immunodeficiency virus-associated lymphomas

Anas Younes, MD, is the Chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center and Professor ofMedicine at Weill-Cornell Medical College, New York, NY, USA. He has extensive experience in clinical and translational research in lymphoma. He was the Principal Investigator of the MD Anderson Cancer Center LymphomaSPORE grant, and is currently the Principal Investigator of the Memorial Sloan Kettering Cancer Center Lymphoma SPORE grant. He has lead more than 60 clinical trials in lymphoma. He has lead, in collaboration with colleagues from around the world, the pivotal trials that resulted in the US FDA approval of brentuximab vedotin and nivolumab for the treatment of patients with relapsed Hodgkin lymphoma. He has published more than 250 papers on lymphoma.

• Introduction.- Risk factors, etiology, and pathogenesis.- World Health Organization classification.- Staging.- Treatment overview.- Treatment of B-cell lymphomas.- Treatment of T-cell lymphomas.- Treatment of Hodgkin lymphoma.- Management of human immunodeficiency virus-associated lymphomas

Anas Younes, MD, is the Chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center and Professor ofMedicine at Weill-Cornell Medical College, New York, NY, USA. He has extensive experience in clinical and translational research in lymphoma. He was the Principal Investigator of the MD Anderson Cancer Center LymphomaSPORE grant, and is currently the Principal Investigator of the Memorial Sloan Kettering Cancer Center Lymphoma SPORE grant. He has lead more than 60 clinical trials in lymphoma. He has lead, in collaboration with colleagues from around the world, the pivotal trials that resulted in the US FDA approval of brentuximab vedotin and nivolumab for the treatment of patients with relapsed Hodgkin lymphoma. He has published more than 250 papers on lymphoma.

• Introduction.- Risk factors, etiology, and pathogenesis.- World Health Organization classification.- Staging.- Treatment overview.- Treatment of B-cell lymphomas.- Treatment of T-cell lymphomas.- Treatment of Hodgkin lymphoma.- Management of human immunodeficiency virus-associated lymphomas